T he goal for the optimal treatment of the patient with severe aortic stenosis (AS) is the proper timing of the only effective therapy for the disease (aortic valve replacement [AVR]) in such a way as to prevent sudden death and to maximize the patient's quality of life.
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For the patient with severe AS who develops the classic symptoms of angina or syncope or those of heart failure (primarily dyspnea on exertion), management is one of the most straightforward in medicine. Either the patient undergoes AVR or begins to suffer a mortality rate of Ϸ2% per month. [1] [2] [3] [4] Thus, roughly 75% of symptomatic patients with severe AS will die within 3 years of symptom onset without AVR ( Figure 1 ). 3 Furthermore, AVR is also salutary by improving the quality of life because it relieves symptoms.
The asymptomatic patient with severe AS poses a much more difficult management decision. AVR will not improve the quality of life (the patient is asymptomatic), and furthermore, most such patients have a good short-term prognosis, with a risk of sudden death of Ͻ1% per year. 1, 5, 6 The obvious problem is that this risk of sudden death is not zero. Given the opportunity to observe enough patients with asymptomatic severe AS, the practitioner likely will experience a patient who dies suddenly and unexpectedly, a terrible consequence for the patient, as well as the family and the physician.
Every physician carries a scale in the back of his or her mind with which to weigh the risk and benefit of every decision that he or she makes. The physician proceeds when benefit outweighs the risk and desists when risk outweighs benefit. In the case of the patient with asymptomatic AS, it is the risk of sudden death or increased operative risk that accrues from waiting versus the risk of early AVR that must be taken into consideration. Without randomized clinical trials to guide the clinician, this decision is one of the most difficult in cardiology.
The Definition of Severe AS
The current American Heart Association/American College of Cardiology guidelines for the management of patients with valvular heart disease (for which this writer was an author) define severe AS as a patient with an aortic valve area of Յ1.0 cm 2 (or 0.6 cm 2 /m 2 ) or a peak transaortic jet velocity of Ն4.0 m/s or a mean transvalvular gradient of Ն40 mm Hg. 7 Throughout the 2006 guidelines, the often-used adjective critical to describe AS is entirely avoided. The committee recognized that it could arbitrarily define severe as noted above, but that it could not determine the valve area that was critical (life-threatening) for a given individual. AS, as defined above, casts a wide net. It includes the vast majority of patients at risk for developing symptoms and thus sudden death. However, there are many patients with AS who fit this technical definition who do not manifest the consequences of severe left ventricular (LV) outflow obstruction. They do not demonstrate severe LV hypertrophy or systolic or diastolic LV dysfunction, nor are their physical examinations typical of the examination of patients with severe AS. In other words, this definition is sensitive but less specific for critical AS. Yet almost all would agree that AVR is not indicated in asymptomatic patients unless AS is truly life-threatening. Thus, for the purposes of this discussion, severe AS is defined as it was in the recent landmark randomized trial of transcatheter AVR 4 as a valve area Յ0.8 cm 2 . Although this is obviously arbitrary, so is the aortic valve area of 1.0 cm 2 , and the smaller valve area shifts the risk-benefit ratio further toward benefit for AVR, because the risk of waiting is higher.
The Risk of Waiting
As noted above, sudden death is the major risk of waiting for symptoms to develop in the patient with severe AS. Furthermore, at a death rate of 2% per month once symptoms occur, some patients will die very soon after symptom onset. 8 Even if patients are followed up every 6 months, there is a substantial window of time for symptoms to develop (and for death to occur) between visits to the physician. A potential solution is to caution patients to alert their healthcare providers immediately if a symptom typical of AS occurs, but the success of this strategy is unknown. Additionally, patients may simply not recognize their symptoms or deny them, thus putting themselves at a substantial risk of death without realizing the gravity of this clinical change.
Exercise Testing
An important adjunct in assessing a patient's symptomatic status is the formal exercise test. Although it is clearly dangerous and in fact contraindicated to subject a patient with symptomatic AS to exercise, exercising the patient who claims to be asymptomatic is both safe and extremely helpful for detecting latent symptoms or unrecognized exerciseinduced hemodynamic instability. 9 -11 Importantly, patients unaware of latent symptoms will exercise as part of their daily lives, putting themselves at risk every time they engage in activity. Logically, it seems wiser to uncover such instability under the watchful eye of the physician than to have it occur when the patient is alone and unprotected. Exercise testing of asymptomatic patients with severe AS conveys substantial prognostic information, uncovering latent symptoms or hemodynamic instability in one third to one half of such patients ( Figure 2 ). 10 Those patients with a positive test (defined in different studies as failure to achieve a rise in blood pressure or the occurrence of symptoms or unexpected reduction in exercise tolerance) are likely to need an AVR for the development of symptoms within a year. 9, 10 As such, it is easy to argue that early AVR now rather than when frank symptoms develop is warranted in patients with a positive test.
Rapidity of Progression
Several studies have examined the rate of progression of AS by examining transvalvular gradient and aortic valve area at 2 or more points in time. [12] [13] [14] [15] [16] [17] [18] [19] Not surprisingly, AS progression is quite variable; however, it is more rapid in more severely calcified valves and in more severely stenotic valves. 20 That there are several similarities between atherosclerosis [21] [22] [23] and AS raised the possibility that statin drugs, so effective in treating coronary artery disease, might retard the progression of AS. Unfortunately, several randomized trials examining the effect of different statins on patients with differing levels of AS severity all found that statins failed to prevent disease progression. 24 -26 Thus, this form of medical therapy does not enter into the decision regarding whether or not to defer AVR until symptoms occur, because there is no evidence that symptom onset can be delayed.
On average, valve area decreases by Ϸ0.1 cm 2 per year and mean gradient increases by Ϸ7 mm Hg per year [12] [13] [14] [15] [16] [17] [18] [19] ; however, in some patients, gradient can increase by as much as 20 mm Hg in a single year. Quite predictably, the more severe the AS, the sooner the progression to symptoms, with patients who demonstrate a peak jet velocity of 4 m/s requiring an AVR within 2 years in most cases and patients with a jet velocity Ͼ5 m/s requiring an AVR within 1 year. 27, 28 Thus, for the patient whose valve area is Յ0.8 cm 2 , it is becomes very likely that AVR will be required because of symptom onset in 2 years or substantially sooner (if serial measurements show rapid progression), during which time the patient will become 2 years older. If no comorbidities develop during those 2 years, the Society of Thoracic Surgeons risk calculator 29 for cardiac surgery projects that as age increases from 73 to 75 years, absolute operative mortality risk increases by 0.1% and combined mortality and serious morbidity increases by 0.5%. Obviously, if new significant health factors intervene, the risks of waiting are still higher, which raises the argument that surgery could be performed more safely now than 2 years from now; thus, little may be gained by waiting for symptoms to occur.
LV Hypertrophy
The pressure overload created by AS leads to the development of concentric LV hypertrophy (LVH). The role of LVH in AS has been debated for decades. On one hand, wall thickening helps to normalize excessive afterload placed on the LV by increased LV systolic pressure. Afterload can be quantified by Laplace's law as systolic wall stress (), where ϭpressureϫradius/2 thickness. Thus, increased pressure in the Laplace numerator can be offset by increased wall thickness in the denominator. As such, LVH can be viewed as a compensatory mechanism, and substantial evidence exists to show that LVH does in fact help to preserve ejection performance in subjects with AS. 30 -32 On the other hand, the presence of LVH in AS and other cardiac diseases is associated with increased mortality and increased risk of heart failure, especially in the presence of coronary artery disease. [33] [34] [35] In a recent study of nearly 2000 propensitymatched AS patients undergoing AVR, those with substantial concentric LVH experienced twice the mortality and twice the morbidity of patients without significant LVH. 36 Thus, if waiting for symptoms to develop also allows time for excessive LVH to develop, earlier rather than later surgery may be associated with a better outcome.
Brain Natriuretic Peptide
It is obvious from the foregoing discussion that symptom onset is a key demarcation point in the natural history of AS. However, detection of symptoms is in part predicated on the skill of the interviewer, as well as on the ability of the patient to recognize and admit to symptoms when they become present. Because symptomatic state is so important yet so subjective in nature, markers that might more objectively forecast the need for surgery have been sought. Brain natriuretic peptide (BNP) and its precursor, proBNP, have been studied extensively as potential symptom surrogates. [37] [38] [39] [40] [41] [42] The Table lists outcomes in asymptomatic patients and how they relate to BNP or proBNP levels. Although there is no unanimity regarding a specific BNP benchmark that would substitute for symptom onset in the decision to opt for AVR, it appears that a rising BNP or proBNP level in a given patient is a worrisome sign and a point in favor of early AVR.
Age and Patient Expectations
It cannot be the goal of therapy to extend life forever, and the risk of dying of any cause is obviously much greater at age 80 years of age than at age 50. Accordingly, many would feel that sudden death is far more tragic in the 50-year-old than in someone who has lived most of his or her natural life span. Thus, age must be considered in the decision to recommend AVR to the asymptomatic AS patient, and desired lifestyle also must be taken into account. A recommendation for AVR in the asymptomatic 80-year-old whose passion is to ski at high altitudes seems much more reasonable than to recommend AVR to the sedentary 80-year-old who is happy with his current lifestyle and also wary of cardiac surgery.
The Risk of AVR
Obviously, the potential benefit of early surgery must be carefully weighed against the risk of the operation (AVR). The risk of AVR is predicated both on the risk factors presented by the patient and on the skill and experience of the cardiovascular team performing the surgery. In some centers, this risk has become very low. For instance, 1 center recently reported 190 consecutive AVRs without a death. 43 For a 70-year-old man with severe AS but without coronary disease or other systemic comorbidities, the Society of Thoracic Surgeons risk calculator projects a mortality risk of just 0.8% and a combined mortality plus serious morbidity rate of 8.2%. Although reliable, this risk calculator often overestimates the risk seen in actual practice, 29, 44 so that actual risk is even less. Thus, the operation in experienced hands is quite safe, and operative risk may be so small as to be less than the risk of sudden death in asymptomatic patients. Figure 3 examines estimated operative risk and morbidity according to age in asymptomatic patients without comorbidities.
In addition to operative risk, the risk of postoperative valve-related complications must be considered. These are well known to primarily be structural valve deterioration in bioprosthetic valves and thromboembolic/hemorrhagic complications in mechanical valves. However, for the patient with a valve area of Ͻ0.8 cm 2 discussed herein, symptoms will develop in the large majority within 2 years, after which a valve would be implanted anyway. Thus, only the valverelated risk in the time period between early surgery and when AVR would be performed for symptoms should be considered as excess risk, at probably 1% to 2%.
Transcatheter Valve Implantation
Currently, transcatheter valves are implanted for inoperable patients or those at very high risk for AVR. Very few, if any, such patients are asymptomatic, and thus, transcatheter AVR currently has no place in this discussion. However, we are only at the dawn of this exciting new field. If technology were to develop valves with long durability and negligible risk, it is conceivable that such a valve might be considered for asymptomatic patients with severe AS. Vetting of this concept would appear to be years away but could dynamically affect the therapy of asymptomatic AS patients in the future.
Summary
Only a few decades ago, most experts, including this writer, would have recommended against AVR for asymptomatic patients with AS because the risk of early surgery exceeded its benefit. However, since then, we have become capable of recognizing asymptomatic patients at higher than average risk for whom AVR appears prudent, whereas the risk of both AVR and of postoperative valve-related complications has diminished. Thus, it appears reasonable to perform AVR for asymptomatic patients with an aortic valve area Ͻ0.8 cm 2 who also have any of the following: (1) A positive exercise test, (2) heavy valve calcification, (3) documented rapid progression of AS from serial measurements, (4) excessive LVH, or (5) rising natriuretic peptides, providing the patient is referred to a surgical team with an established track record of excellent operative outcomes. Ultimately, a randomized trial could answer the question, but until such a trial is performed, we will have to continually wrestle with this issue using our best judgment on a case-by-case basis.
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